Drugs / CB03-154
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05502549 | Nov 2022 → Nov 2023 | — | Shanghai Zhimeng Biopharma, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05499260 | May 2022 → Mar 2023 | — | Shanghai Zhimeng Biopharma, Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07238868 | Aug 2025 → Jan 2029 expected | focal epilepsy | Shanghai Zhimeng Biopharma, Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT06612775 | Sep 2024 → Aug 2026 overdue | focal epilepsy | Shanghai Zhimeng Biopharma, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07082192 | Sep 2025 → Sep 2027 expected | amyotrophic lateral sclerosis | Shanghai Zhimeng Biopharma, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CB03-154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07238868 ↗ |
| Route | Oral | “Participants will receive CB03-154 5mg orally once daily in a fasted state.” NCT05499260 ↗ |